A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)
一项针对 BRAF V600E 突变转移性结直肠癌的艾立布林多中心 II 期研究:BRAVERY 研究 (EPOC1701)
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105839
Masuishi, T; Taniguchi, H; Kotani, D; Bando, H; Komatsu, Y; Shinozaki, E; Sunakawa, Y; Satoh, T; Nishina, T; Esaki, T; Wakabayashi, M; Nomura, S; Takahashi, K; Ono, H; Hirano, N; Fujishiro, N; Fuse, N; Sato, A; Sakamoto, Y; Kuramoto, N; Miki, I; Ichiki, H; Nakamura, Y; Sharma, G; Skrzypczak, S; Schultz, E; Kingsford, C; Ohtsu, A; Yoshino, T